Abstract
Introduction: Human pluripotent stem cells (hPSCs) are capable of differentiating into all types of cells in the body and so provide suitable toxicology screening systems even for hard-to-obtain human tissues. Since hPSCs can also be generated from differentiated cells and current gene editing technologies allow targeted genome modifications, hPSCs can be applied for drug toxicity screening both in normal and disease-specific models. Targeted hPSC differentiation is still a challenge but cardiac, neuronal or liver cells, and complex cellular models are already available for practical applications. Areas covered: The authors review new gene-editing and cell-biology technologies to generate sensitive toxicity screening systems based on hPSCs. Then the authors present the use of undifferentiated hPSCs for examining embryonic toxicity and discuss drug screening possibilities in hPSC-derived models. The authors focus on the application of human cardiomyocytes, hepatocytes, and neural cultures in toxicity testing, and discuss the recent possibilities for drug screening in a ‘body-on-a-chip’ model system. Expert opinion: hPSCs and their genetically engineered derivatives provide new possibilities to investigate drug toxicity in human tissues. The key issues in this regard are still the selection and generation of proper model systems, and the interpretation of the results in understanding in vivo drug effects.
| Original language | English |
|---|---|
| Pages (from-to) | 61-75 |
| Number of pages | 15 |
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2 2019 |
Fingerprint
Keywords
- body-on-a-chip
- cardiomyocytes
- directed hPSC differentiation
- hepatocytes
- Human pluripotent stem cells (hPSCs)
- model cells for toxicity screening
- neural cell cultures
- stem cell-derived cellular models
ASJC Scopus subject areas
- Toxicology
- Pharmacology
Cite this
Application of human pluripotent stem cells and pluripotent stem cell-derived cellular models for assessing drug toxicity. / Apáti, A.; Varga, Nóra; Berecz, Tünde; Erdei, Zsuzsa; Homolya, L.; Sarkadi, B.
In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 15, No. 1, 02.01.2019, p. 61-75.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Application of human pluripotent stem cells and pluripotent stem cell-derived cellular models for assessing drug toxicity
AU - Apáti, A.
AU - Varga, Nóra
AU - Berecz, Tünde
AU - Erdei, Zsuzsa
AU - Homolya, L.
AU - Sarkadi, B.
PY - 2019/1/2
Y1 - 2019/1/2
N2 - Introduction: Human pluripotent stem cells (hPSCs) are capable of differentiating into all types of cells in the body and so provide suitable toxicology screening systems even for hard-to-obtain human tissues. Since hPSCs can also be generated from differentiated cells and current gene editing technologies allow targeted genome modifications, hPSCs can be applied for drug toxicity screening both in normal and disease-specific models. Targeted hPSC differentiation is still a challenge but cardiac, neuronal or liver cells, and complex cellular models are already available for practical applications. Areas covered: The authors review new gene-editing and cell-biology technologies to generate sensitive toxicity screening systems based on hPSCs. Then the authors present the use of undifferentiated hPSCs for examining embryonic toxicity and discuss drug screening possibilities in hPSC-derived models. The authors focus on the application of human cardiomyocytes, hepatocytes, and neural cultures in toxicity testing, and discuss the recent possibilities for drug screening in a ‘body-on-a-chip’ model system. Expert opinion: hPSCs and their genetically engineered derivatives provide new possibilities to investigate drug toxicity in human tissues. The key issues in this regard are still the selection and generation of proper model systems, and the interpretation of the results in understanding in vivo drug effects.
AB - Introduction: Human pluripotent stem cells (hPSCs) are capable of differentiating into all types of cells in the body and so provide suitable toxicology screening systems even for hard-to-obtain human tissues. Since hPSCs can also be generated from differentiated cells and current gene editing technologies allow targeted genome modifications, hPSCs can be applied for drug toxicity screening both in normal and disease-specific models. Targeted hPSC differentiation is still a challenge but cardiac, neuronal or liver cells, and complex cellular models are already available for practical applications. Areas covered: The authors review new gene-editing and cell-biology technologies to generate sensitive toxicity screening systems based on hPSCs. Then the authors present the use of undifferentiated hPSCs for examining embryonic toxicity and discuss drug screening possibilities in hPSC-derived models. The authors focus on the application of human cardiomyocytes, hepatocytes, and neural cultures in toxicity testing, and discuss the recent possibilities for drug screening in a ‘body-on-a-chip’ model system. Expert opinion: hPSCs and their genetically engineered derivatives provide new possibilities to investigate drug toxicity in human tissues. The key issues in this regard are still the selection and generation of proper model systems, and the interpretation of the results in understanding in vivo drug effects.
KW - body-on-a-chip
KW - cardiomyocytes
KW - directed hPSC differentiation
KW - hepatocytes
KW - Human pluripotent stem cells (hPSCs)
KW - model cells for toxicity screening
KW - neural cell cultures
KW - stem cell-derived cellular models
UR - http://www.scopus.com/inward/record.url?scp=85059060071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059060071&partnerID=8YFLogxK
U2 - 10.1080/17425255.2019.1558207
DO - 10.1080/17425255.2019.1558207
M3 - Review article
VL - 15
SP - 61
EP - 75
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 1
ER -